Amgen Inc. (AMGN)
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen: Riding The MariTide Of Monthly Weight Loss
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism and less frequent dosing could enhance weight loss and diabetes management, potentially capturing a significant market share. Analysts project MariTide could generate $5 billion in peak annual revenue, bolstering Amgen's growth amidst competition from Eli Lilly, Novo Nordisk, and others.
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
3 Magnificent Growth Stocks to Buy in March
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up.
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ET Company Participants Jay Bradner - Executive Vice President and Head, R&D Justin Claeys - Vice President, IR Conference Call Participants Yaron Werber - TD Cowen Yaron Werber Well, good morning everybody, and thanks once again for joining us at the 45th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team and it's a great pleasure to moderate the next fireside chat with Amgen.
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly, which are weekly injectables.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Final Trades: Berkshire Hathaway, Amgen, Prologis and 3M
The Investment Committee give you their top stocks to watch for the second half.
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen Stock: Why I Still Rate It A 'Buy'
